More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。